HemaCare (OTCMKTS:HEMA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The brokerage presently has a $16.00 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 15.11% from the company’s previous close.

According to Zacks, “HEMACARE CORP.’s business activities include blood management programs, regional sales of blood products and blood services. Their Blood Management Programs enable hospitals to contract out all or a portion of their blood services activities, which include donor center management, blood procurement and other blood related activities. Blood Products include apheresis platelets and whole blood components, such as red blood cells and plasma products. Blood Services include therapeutic apheresisprocedures, stem cell collection and donor testing services. “

OTCMKTS HEMA traded down $0.15 during trading on Thursday, reaching $13.90. 72,130 shares of the company’s stock were exchanged, compared to its average volume of 10,732. HemaCare has a fifty-two week low of $8.40 and a fifty-two week high of $15.20. The company’s fifty day simple moving average is $12.76 and its 200-day simple moving average is $12.71.

HemaCare Company Profile

HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.

See Also: What is the Ex-Dividend Date in Investing?

Get a free copy of the Zacks research report on HemaCare (HEMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.